Obesity Market Snapshot: Competition Is Good For Everyone, Especially Orexigen
Executive Summary
With more than two years of competition behind them, it’s becoming clear that latecomer Contrave might just be the star of the obesity drug market, while its competitors are stuck playing second fiddle. Yet, all players are benefiting from increased obesity sales reps in the field.
You may also be interested in...
Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
Arena Looking To Puff Up Belviq Sales With Smoking Indication
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.